Table 3d Multivariate analysis for each event KIR ligand incompatibility in the HVG direction with AML patients

Variables	Reference	HR	95% CI		P-value
Overall survival
KIR incompatible	Compatible	0.73	0.46	1.18	0.197
Age >40	Age 0–15	2.00	1.02	3.93	0.045
Male	Female	1.76	1.21	2.58	0.003
CR2–	CR1	0.74	0.50	1.08	0.120
HLA mismatching (>5/6)	HLA mismatching (6/6, 5/6)	1.09	0.72	1.65	0.681
Disease-free survival
KIR incompatible	Compatible	0.83	0.53	1.30	0.414
Age >40	Age 0–15	1.33	0.72	2.45	0.357
Male	Female	1.48	1.03	2.11	0.032
CR2–	CR1	0.76	0.53	1.09	0.131
HLA mismatching (>5/6)	HLA mismatching (6/6, 5/6)	1.03	0.70	1.51	0.893
Relapse incidence
KIR incompatible	Compatible	0.86	0.42	1.75	0.68
Age >40	Age 0–15	0.67	0.29	1.58	0.36
Male	Female	1.09	0.62	1.91	0.76
CR2–	CR1	0.75	0.42	1.34	0.330
HLA mismatching (>5/6)	HLA mismatching (6/6, 5/6)	0.98	0.55	1.76	0.950
Non-relapse mortality
KIR incompatible	Compatible	0.88	0.49	1.57	0.66
Age >40	Age 0–15	2.62	1	6.88	0.051
Male	Female	1.69	1.05	2.74	0.032
CR2–	CR1	0.84	0.53	1.35	0.480
HLA mismatching (>5/6)	HLA mismatching (6/6, 5/6)	1.08	0.64	1.83	0.770
Engraftment
KIR-incompatible	Compatible	0.799	0.59	1.084	0.15
Age >40	Age 0–15	0.958	0.68	1.352	0.81
Male	Female	0.918	0.72	1.17	0.49
CR2–	CR1	0.994	0.78	1.264	0.96
HLA mismatching (>5/6)	HLA mismatching (6/6, 5/6)	0.997	0.77	1.291	0.98
Infused cell >2.5 × 10⁷/kg	≦2.5	1.387	1.07	1.8	0.014
MAC	RIC	0.694	0.53	0.914	0.009
Acute GVHD
KIR-incompatible	Compatible	1.20	0.76	1.90	0.42
Age >40	Age 0–15	0.51	0.28	0.96	0.035
Male	Female	1.09	0.75	1.59	0.64
CR2–	CR1	0.98	0.66	1.45	0.910
HLA mismatching (>5/6)	HLA mismatching (6/6, 5/6)	1.49	0.95	2.34	0.086

Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; CR, complete remission; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; HR, hazard ratio; HVG, host-versus-graft; KIR, killer cell immunoglobulin-like receptor; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.

Search